Chemistry:Glecirasib
From HandWiki
Glecirasib (JAB-21822) is a pharmaceutical drug used for cancer treatment. It is a selective inhibitor of the G12C mutant version of the enzyme KRAS. It is used as a combination treatment alongside other selective enzyme inhibitors.[1][2][3][4]
References
- ↑ "Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial". Nature Medicine 31 (3): 894–900. March 2025. doi:10.1038/s41591-024-03401-z. PMID 39762419.
- ↑ "Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future". European Journal of Pharmacology 996. June 2025. doi:10.1016/j.ejphar.2025.177428. PMID 40024323.
- ↑ "Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials". The Lancet. Gastroenterology & Hepatology 11 (2): 110–123. February 2026. doi:10.1016/S2468-1253(25)00267-5. PMID 41344351.
- ↑ "Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials". Cancer Communications 45 (11): 1500–1512. November 2025. doi:10.1002/cac2.70056. PMID 41037823.
 |  |
